Key Highlights

• Bio-Techne (NASDAQ: TECH) and Merck KGaA, Darmstadt, Germany, announced a definitive merger agreement on June 25, 2026.

• The deal involves a wholly-owned subsidiary of Merck KGaA acquiring Bio-Techne in an all-cash transaction.

• Bio-Techne will file a proxy statement on Schedule 14A with the SEC, detailing the proposed transaction for shareholders.

• Forward-looking statements in the announcement include risks related to integration, regulatory approvals, and market conditions.

Deal Announcement Details

Bio-Techne (NASDAQ: TECH) and Merck KGaA, Darmstadt, Germany, disclosed a binding merger agreement on June 25, 2026. The transaction will see Merck KGaA’s wholly-owned subsidiary, EMD Holdings NewCo, Inc. Acquire the Minnesota-based biotech firm. A joint press release outlining the terms was filed as Exhibit 99.1 in a Form 8-K submission.

Transaction Structure

The merger involves an all-cash offer, though specific financial terms remain undisclosed. Bio-Techne shareholders will vote on the proposal, with the company preparing to file a proxy statement on Schedule 14A. The deal’s completion hinges on regulatory clearances and shareholder approval.

Regulatory and Shareholder Steps

Bio-Techne will submit the proxy statement to the SEC, providing investors with critical details ahead of a vote. The filing will include risks, timelines, and potential impacts on TECH stock. Shareholders are advised to review these documents once available, as they will contain essential information about the merger’s structure and implications.

Integration and Market Risks

The announcement highlights forward-looking statements, including integration challenges and regulatory hurdles. Merck KGaA’s ability to realize anticipated synergies and retain key Bio-Techne employees remains a focal point. Market volatility, currency fluctuations, and intellectual property risks are also noted as potential obstacles.

Forward-Looking Statements

Both companies cautioned that actual results may differ from projections due to unforeseen risks. Factors such as delays in obtaining approvals, competing offers, or business disruptions could impact the deal’s timeline. Investors are urged not to rely solely on these statements, which reflect expectations as of June 25, 2026.

Proxy Solicitation Process

Bio-Techne’s directors and executive officers, along with Merck KGaA’s leadership, may participate in proxy solicitation efforts. Updated ownership disclosures will be filed with the SEC on Forms 3 and 4. The proxy statement will outline participants’ interests and direct or indirect holdings in Bio-Techne.

Next Steps for Investors

Bio-Techne shareholders should monitor SEC filings and the company’s investor relations page for updates. The merger’s success depends on meeting regulatory conditions and securing majority shareholder support. No further financial details have been released, but the deal’s progress will be closely watched by industry analysts.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.